| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 05/27/2004 | US20040102394 Using compositions comprising oligonucleotides targeted to nucleic acid encoding huntingtin interacting protein 2; for diagnosis and treatment of disease associated with expression of huntingtin interacting protein 2 |
| 05/27/2004 | US20040102391 Using compounds, especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding Gankyrin, and which modulate the expression of Gankyrin |
| 05/27/2004 | US20040102390 Modulation of Notch3 expression |
| 05/27/2004 | US20040102389 Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| 05/27/2004 | US20040102382 Targeting peptides |
| 05/27/2004 | US20040102379 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 05/27/2004 | US20040102372 Therapeutic antiangiogenic compositions and methods |
| 05/27/2004 | US20040102371 Encoded amino acid sequences, DNAs encoding the proteins, recombinant vectors, culturing, drugs comprising the proteins or DNAs, antibodies, drug screening, for arteriosclerosis, hyperlipidemia, obesity or mellitus diabetes |
| 05/27/2004 | US20040102367 Gene expression system based on chimeric receptors |
| 05/27/2004 | US20040102349 Textiles, hard surfaces; storage stability |
| 05/27/2004 | US20040101965 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/27/2004 | US20040101964 Serum albumin drugs for gene therapy; aggregation suppression |
| 05/27/2004 | US20040101963 Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus |
| 05/27/2004 | US20040101957 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
| 05/27/2004 | US20040101946 Method of using ammonia-oxidizing bacteria |
| 05/27/2004 | US20040101942 Sulfohydrolases, corresponding amino acid and nucleotide sequences, sulfohydrolase preparations, processes, and products thereof |
| 05/27/2004 | US20040101940 Identification of a new cytotoxic activity from the ink of aplysia punctata |
| 05/27/2004 | US20040101936 Modifying a gene encoding an avermectin aglycon synthase to obtain a modified enzyme and allowing a N-acetylcystamine thioester, which is a substrate of the modified enzyme, to act on a cell in which modified genes have been expressed |
| 05/27/2004 | US20040101932 Compositions and methods for targeted enzymatic release of cell regulatory compounds |
| 05/27/2004 | US20040101931 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 05/27/2004 | US20040101929 Comprises transgenic yellow grouper brain cell expressing immunoglobulin complex which prevents viral infection in teleost farms; animal husbandry and veterinary medicine |
| 05/27/2004 | US20040101928 Transforming escherichia with humicola nucleotide sequences coding lipase for use in preparation of detergents and baking materials |
| 05/27/2004 | US20040101919 Detecting cell wall anchored surface proteins and developing vaccines to diagnose, prevent and treat enterococcus, streptococcus, staphylococcus and bacillus infections |
| 05/27/2004 | US20040101915 Diagnosis and treatment of chemoresistant tumors |
| 05/27/2004 | US20040101911 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 05/27/2004 | US20040101907 Characterization of the gsk-3beta protein and methods of use thereof |
| 05/27/2004 | US20040101895 Fta-coated media for use as a molecular diagnostic tool |
| 05/27/2004 | US20040101894 Microarrays having multiple oligonucleotides in single array features |
| 05/27/2004 | US20040101893 Abasic site endonuclease assay |
| 05/27/2004 | US20040101889 Method of detection by enhancement of silver staining |
| 05/27/2004 | US20040101888 Vector system used in screening active substances |
| 05/27/2004 | US20040101887 Comprises conjugate beta-arrestin/green fluorescent protein fusion for identifying modulators of g-protein coupled receptor kinases; drug screening; vasodilation and cardiovascular disorders |
| 05/27/2004 | US20040101882 Secreted proteins |
| 05/27/2004 | US20040101880 Comprises expression vector for use as gene targeting and transfer agent; gene therapy and animal models of disease |
| 05/27/2004 | US20040101872 Lipocalins |
| 05/27/2004 | US20040101871 Regulation of human gpcr-like protein |
| 05/27/2004 | US20040101869 Liposome; virus protein overcoating of interior nucleic acid; quantitative analysis |
| 05/27/2004 | US20040101865 Comprises nucleotide sequences coding polypeptides associated with biosynthesis and metabolism of acetyl-CoA for preparing food, feed, cosmetics and pharmaceutical agents |
| 05/27/2004 | US20040101858 Modulation of hypoxia-inducible factor 1 alpha expression |
| 05/27/2004 | US20040101857 Modulation of cytokine-inducible kinase expression |
| 05/27/2004 | US20040101856 Antisense nucleotide sequences for treatment of hyperproliferative disorders |
| 05/27/2004 | US20040101854 Modulation of BCL2-associated athanogene expression |
| 05/27/2004 | US20040101852 Antisense nucleotide sequences for treatment of neurodegenerative diseases |
| 05/27/2004 | US20040101850 Antisense nucleotide sequences for treatment of hyperactive immune response disorders |
| 05/27/2004 | US20040101849 Modulation of selenoprotein W expression |
| 05/27/2004 | US20040101848 Antisense nucleotide sequences for treatment of hyperproliferative disorders |
| 05/27/2004 | US20040101847 Antisense nucleotide sequences for treatment of autoimmune diseases |
| 05/27/2004 | US20040101841 Plant promoter |
| 05/27/2004 | US20040101837 Nucleotide sequences coding for proteins involved in the biosynthesis of L-serine, an improved method for the microbial production of L-serine and a genetically modified microorganism suitable therefor |
| 05/27/2004 | US20040101835 Using circularized probe to detect, amplify and sequence target nucleotide sequences; restriction fragment length polymorphisms |
| 05/27/2004 | US20040101833 Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and riluzole |
| 05/27/2004 | US20040101832 Everninomicin biosynthetic genes |
| 05/27/2004 | US20040101831 Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| 05/27/2004 | US20040101827 Methods of infection with hepatitis c virus |
| 05/27/2004 | US20040101825 Comprises expression vector coding hypoxia inducible factors, regulatory elements and antitumor agents for transformation and destruction of tumor cells |
| 05/27/2004 | US20040101821 Antiviral antisense therapy |
| 05/27/2004 | US20040101820 Polynucleotide probe and primer originating in hepatitis e virus of japanese, chips having the same, kits having the same and method of detecting hepatits e virus using the same |
| 05/27/2004 | US20040101536 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group B streptococcal carbohydrates |
| 05/27/2004 | US20040101533 Fusion protein; antitumor, anticancer agenst |
| 05/27/2004 | US20040101529 Regulation of human serine-threonine protein kinase |
| 05/27/2004 | US20040101528 Type I IL-1 receptors |
| 05/27/2004 | US20040101520 Recombination method |
| 05/27/2004 | US20040101514 High transgene expression of a pseudotyped adeno-associated virus type |
| 05/27/2004 | US20040101512 Adenoviral vectors for treating disease |
| 05/27/2004 | US20040101509 Chemokine mutants in the treatment of multiple sclerosis |
| 05/27/2004 | US20040100284 Method for detecting PCR product using electrical signal |
| 05/27/2004 | DE10253351A1 Isolation of nucleic acid by binding to solid phase, useful e.g. in forensic or diagnostic medicine, uses binding buffer containing monovalent and multivalent ions, eliminates need for alcohol in wash buffer |
| 05/27/2004 | DE10252245A1 Producing a protein useful as pharmaceuticals, e.g. medicine and vaccine, or in food or paper production, comprises expressing and secreting a protein expressed by Zygosaccharomyces bailii strain |
| 05/27/2004 | CA2757475A1 Compositions and methods for the treatment of natural killer cell related diseases |
| 05/27/2004 | CA2505931A1 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 05/27/2004 | CA2505895A1 Expression profiling based on histocultures |
| 05/27/2004 | CA2505868A1 Ligands |
| 05/27/2004 | CA2505807A1 Dna sequences from tcd genomic region of photorhabdus luminescens |
| 05/27/2004 | CA2505801A1 Antisense modulation of apolipoprotein b expression |
| 05/27/2004 | CA2505724A1 Malaria vaccine |
| 05/27/2004 | CA2505623A1 Plant stress tolerance genes, and uses therefor |
| 05/27/2004 | CA2505573A1 Benzoate inducible promoters |
| 05/27/2004 | CA2505558A1 T cell receptor display |
| 05/27/2004 | CA2505546A1 Molecules preferentially associated with effector t cells and methods of their use |
| 05/27/2004 | CA2505423A1 A method to produce succinic acid from raw hydrolysates |
| 05/27/2004 | CA2505414A1 Lipophilic phosphoramide compounds and uses thereof |
| 05/27/2004 | CA2505403A1 Modified dendritic cells |
| 05/27/2004 | CA2505330A1 Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| 05/27/2004 | CA2505197A1 Use of edg2 receptor in an animal model of heart failure |
| 05/27/2004 | CA2505090A1 Conjugated oligomeric compounds and their use in gene modulation |
| 05/27/2004 | CA2504953A1 A new target for angiogenesis and anti-angiogenesis therapy |
| 05/27/2004 | CA2504947A1 Auxin-repressed, dormancy-associated promoter and uses thereof |
| 05/27/2004 | CA2504929A1 Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| 05/27/2004 | CA2504903A1 Method for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | CA2504818A1 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 05/27/2004 | CA2504720A1 Chimeric oligomeric compounds and their use in gene modulation |
| 05/27/2004 | CA2504701A1 Structural motifs and oligomeric compounds and their use in gene modulation |
| 05/27/2004 | CA2504607A1 Methods and compositions for treating neurological disorders |
| 05/27/2004 | CA2504605A1 Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15 |
| 05/27/2004 | CA2504554A1 2'-substituted oligomeric compounds and compositions for use in gene modulations |
| 05/27/2004 | CA2503748A1 Compositions and methods for the treatment of natural killer cell related diseases |
| 05/27/2004 | CA2502822A1 High throughput automatic nucleic acid isolation and quantitation methods |
| 05/27/2004 | CA2502490A1 Transgenic ungulates having reduced prion protein activity and uses thereof |
| 05/26/2004 | EP1422514A1 Method of evaluating uniformity of spots in arrays |
| 05/26/2004 | EP1422298A2 Detection of hiv-1 by nucleic acid amplification |